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A B S T R A C T
The European Food Consumption Validation (EFCOVAL) project includes 600 men and women from Belgium,
the Czech Republic, France, the Netherlands, and Norway, who had given serum and 24-hour urine samples, and
completed 24-hour dietary recall (24-HDR) interviews. Consumption, according to 24-HDR, was matched
against the European Food Safety Authority (EFSA) databases of mycotoxin contaminations, via the FoodEx1
standard classifications, producing an indirect external estimate of dietary mycotoxin exposure. Direct, internal
measurements of dietary mycotoxin exposure were made in serum and urine by ultra-performance liquid
chromatography coupled to tandem mass spectrometry. For the first time, mycotoxin exposures were thoroughly
compared between two 24-HDRs, and two 24-hour urine samples collected during the same days covered by the
24-HDRs. These measurements were compared to a single-time point serum measurement to investigate evi-
dence of chronic mycotoxin exposure. According to 24-HDR data, all 600 individuals were exposed to between 4
and 34 mycotoxins, whereof 10 found to exceed the tolerable daily intake. Correlations were observed between
two time points, and significant correlations were observed between concentrations in serum and urine.
However, only acetyldeoxynivalenol, ochratoxin A, and sterigmatocystin were found to have significant positive
correlations between 24-HDR exposures and serum, while aflatoxin G1 and G2, HT-2 toxin, and deoxynivalenol
were associated between concurrent 24-HDR and 24-hour urine. Substantial agreements on quantitative levels
between serum and urine were observed for the groups Type B Trichothecenes and Zearalenone. Further research is
required to bridge the interpretation of external and internal exposure estimates of the individual on a time scale
of hours. Additionally, metabolomic profiling of dietary mycotoxin exposures could help with a comprehensive
assessment of single time-point exposures, but also with the identification of chronic exposure biomarkers. Such
detailed characterization informs population exposure assessments, and aids in the interpretation of epide-
miological health outcomes related to multi-mycotoxin exposure.
1. Introduction
Over the course of a human lifetime, dietary exposure to mycotoxins
is unavoidable (Andrade and Caldas, 2015; Abrunhosa et al., 2016;
Eskola et al., 2019; Schatzmayr and Streit, 2013; Smith et al., 2016;
Streit et al., 2013; Van Der Fels-Klerx et al., 2012). Even in the highly
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EU-regulated food supply and sanitary living conditions, agricultural
products attract fungal colonization (178/2002/EC, 2002; 1126/2007/
EC, 2007; 1881/2006/EC, 2006; 2006/576/EC, 2006; 2013/165/EU,
2013). Certain fungal secondary metabolites, termed mycotoxins, are
reported in surveys of food crops, in harvest storage, in processed plant-
based foods, and finally in human populations (Eskola et al., 2019;
Blesa et al., 2012; Jodlbauer et al., 2000; De Boevre et al., 2012; Magan
et al., 2011; Pleadin et al., 2015; Scudamore and Livesey, 1998;
Solfrizzo et al., 2014; Heyndrickx et al., 2014). Chronic dietary ex-
posure to multiple mycotoxins throughout the life-course of a human
being is a reality (De Ruyck et al., 2015). The toxicological burden of
mycotoxins has been described in many detailed in vivo studies, and
ranges from gastrointestinal manifestations, genotoxicity, estrogenicity
to death (Smith et al., 2016; De Ruyck et al., 2015; Adam et al., 2017;
Probst et al., 2007; Kamala et al., 2018).
Mycotoxins in the food supply have the opportunity to be absorbed
through the gastrointestinal tract, into the circulatory system. Some
mycotoxins pass unchanged from the farm crop to the blood stream
(Assuncao et al., 2015; Hartinger and Moll, 2011; Kostelanska et al.,
2009; Vidal et al., 2016). The broad variation in physicochemical
properties among mycotoxins, however, leads to a large variation in
rates of absorption, metabolism and excretion (Kiessling et al., 1984).
Indeed, humans significantly metabolize and excrete mycotoxins in a
complex manner, resulting in disparate toxicokinetic profiles (Vidal
et al., 2018; Vidal, 2018; Ringot et al., 2006; Degen et al., 2018).
Subsequently, in assessments of human exposure to mycotoxins, me-
tabolized forms (i.e., biomarkers of exposure), need to be included
when accurately calculating exposure (Berthiller et al., 2011; Nathanail
et al., 2015). The identification and suitability of a reliable mycotoxin
biomarker(s) are pertinent (Vidal et al., 2018; Vidal, 2018; Yang et al.,
2015; Yang et al., 2015; Abnet et al., 2001; Dragusel, 2013). The pro-
duction of glucuronic acid conjugates from deoxynivalenol (DON) and
zearalenone (ZEN) are common examples (Maul et al., 2012; Pfeiffer
et al., 2010; Vidal et al., 2016; Yang et al., 2017). Diacetoxyscirpenol
(DAS) is metabolized into five different forms in vitro by human liver
microsomes and mostly cleared from blood of pigs within 4–6 h (Yang
et al., 2015; Bauer et al., 1985). Some mycotoxins undergo minimal
endogenous metabolism and are detected in their original conforma-
tion, such as the non-polar fumonisins (FB), resulting in low rates of
both absorption and metabolism (Hartinger and Moll, 2011;
Stockmann-Juvala and Savolainen, 2008; Van der Westhuizen et al.,
2013). In certain cases, mycotoxins may affect toxicity by their con-
jugation with cellular DNA, producing mycotoxin-DNA adducts such as
aflatoxin B1 (AFB1)-N7-guanine (Wild et al., 1990). A comprehensive
overview of mycotoxin biomarkers and their toxicokinetic profiles is
detailed in Vidal (2018).
It becomes increasingly interesting to compare biological fluids,
such as urine and blood, to correctly elucidate a comprehensive cross-
section of internal mycotoxin exposures. Considering the chronic nature
of dietary exposure, as well as the variety of a modern diet, modelling
real-world exposure requires the simultaneous assessment of multiple
mycotoxins (Warth et al., 2013). Determining and monitoring myco-
toxin presence informs food safety assessments by indirectly evaluating
a population's probable external exposure, or by directly quantifying
internal exposure through biomarker analysis (Abrunhosa et al., 2016;
Gerding et al., 2014; Heyndrickx et al., 2015; Wallin et al., 2015).
Recently, Gormley et al. (2019) described an increasing interest in
using dietary biomarkers in order to address possible measurement
errors in external exposure estimates (Gormley et al., 2019). Though
dietary analyses are widely used and accessible tools for estimating
population intake of dietary contaminants, complimentary assessments
are required to elucidate the variance among populations. Therefore,
for the first time, the agreement among different multi-mycotoxin in-
ternal exposure measurements and theoretical external exposure esti-
mates was explored in a human population. Single time-point exposures
were compared between 24-hour dietary recall (24-HDR) surveys and
24-hour urine collections from the same day. These measurements were
repeated after one month and also compared to a single time point
serum measurement to investigate evidence of and associations with
chronic mycotoxin exposure. This pioneering work will further advance
research on multiple mycotoxin monitoring on the population level.
2. Methods
2.1. Study design
The comparison of cross-sectional survey methods includes human
populations from five European nations, briefly characterized in
Table 1. The population characterization, dietary data, and biological
samples were obtained from the European Food Consumption Valida-
tion (EFCOVAL) project (Crispim et al., 2011; de Boer et al., 2011).
EFCOVAL cataloged people's dietary intake, and also collected biolo-
gical samples of 24-hour urine and non-fasted serum (de Boer et al.,
2011). These biological samples were analyzed for multiple mycotoxins
by ultra-performance liquid chromatography coupled to tandem mass
spectrometry (UPLC-MS/MS), followed by confirmatory analyses using
high-resolution mass spectrometry (HRMS). The two days on which
measurements were taken were expected to be directly comparable
with urine measurements taken the same day. The mean exposure of
the two days was used to compare against a serum sample taken some
weeks prior to the 24-HDR’s, and also against the mean of the two days’
urine collections, allowing a three-way comparison of different ex-
posure measurements (24-HDR vs. serum; 24-HDR vs. urine; serum vs.
urine).
2.2. Study population
The EFCOVAL project was active from October 2006 until the end of
March 2010. In this dataset, individuals were aged between 45 and
65 years only. Younger and older persons were considered more likely
to experience confounding lifestyle factors (i.e., no regular diets)
(Huybrechts et al., 2011). The research participants in this work were
297 men and 303 women from Belgium, the Czech Republic, France,
the Netherlands, and Norway, allowing consideration of the high di-
versity in dietary patterns around Europe. In EFCOVAL, efforts were
made to ensure a balanced representation of sexes, levels of education,
and regional population centers within each country. Exclusion criteria
were as follows: using diuretics, following a prescribed medical diet,
being enrolled in another study during the same time span, not being
able to read or speak the national language, being pregnant, lactating,
having diabetes mellitus or kidney disease, and donating blood or
plasma during (or<4 weeks before) the study (Huybrechts et al., 2011).
2.3. External exposure estimate
On two days, separated by at least one month, participants were
asked to recall all consumed foods of the previous 24 h, i.e., a 24-HDR
interview (Crispim et al., 2011; Huybrechts et al., 2011). A European
Food Safety Authority (EFSA) dynamic database, including the clus-
tered mycotoxin occurrences of all mycotoxin detections filed by the EU
Member States, was used as a basis for estimating mycotoxin levels in
Table 1
Demographic breakdown of the EFCOVAL project sample.
(N = 600) Belgium Czech
Republic
France the Netherlands Norway
n 123 124 113 122 118
Age (years) 54.7 (5.2) 53.9 (5.9) 55.1 (5.7) 56.3 (5.1) 54.9 (6.4)
Female (%) 48.8 50.0 52.2 50.8 50.8
BMI (kg/m2) 26.2 (4.0) 25.6 (3.2) 24.3 (3.1) 26.0 (4.4) 26.4 (4.2)
Legend: mean values are given, with standard deviations in parenthesis.
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the different foods reported in each 24-HDR from the EFCOVAL parti-
cipants (Eskola et al., 2018; EFSA, 2010). This dataset comprised con-
tamination data of foods with production years from 2001 to 2014, and
sampling years from 1997 to 2014. Noteworthy, the country in which
mycotoxins were detected in a food item was not considered, allowing a
much larger list of food items for all countries in the study. More details
on this dataset are enlisted in the EFSA (2010).
When reporting contaminant concentrations analyzed in monitoring
programs, actual numeric values of concentrations were reported when
the measurements exceed the limit of detection (LOD) or limit of
quantification (LOQ). Therefore, a middle bound (MB)-concentration
scenario was applied for non-detect samples. This implied that for
commodities (e.g., bread) for which there was at least one sample with a
concentration value ≥ LOD or LOQ, all non-detect samples were as-
signed a concentration equal to half the limit value (1/2 LOD or LOQ).
The remaining non-detect samples were assumed to contain no myco-
toxins. This scenario was chosen as a more optimal approach, as op-
posed to assigning all non-detect samples a concentration equal to 0 µg/
kg (i.e., lower bound-scenario). Nevertheless, the lower bound-scenario
was also used in this study for conducting sensitivity analyses.
Following procedures - similar to those that later were standardized
by the European Prospective Investigation into Cancer (EPIC) Nutrient
DataBase (ENDB) project-, food types were aggregated according to the
FoodEx1 standard classifications and assigned a mycotoxin concentra-
tion equal to the median recorded by EFSA (Slimani et al., 2002; EFSA,
2016). Next, for all foods that had been recalled in the 24-HDR, the
same food item (or a proxy/surrogate) was searched in the EFSA food
occurrence database (FoodEx1 item). When all foods reported in a 24-
HDR had been matched with an EFSA FoodEx1 item, then the myco-
toxin data could be linked to the food intake data from EFCOVAL. Since
the EFSA database included several samples that have been analyzed in
one or more laboratories for one single FoodEx1 item, the median of the
mycotoxin values analyzed for all these different samples was used to
perform the linking with the food consumption data. The median ap-
proach was applied rather than the mean, in order to limit the impact of
extreme values on the aggregated FoodEx1 values (EFSA, 2016).
After matching the mycotoxin occurrence data with the food con-
sumption data, the mycotoxin intake was calculated by multiplying the
portion size of the food with the mycotoxin concentration in the food.
Hence, the total intake per day for each mycotoxin was calculated per
individual as the sum of that particular mycotoxin derived from the
different foods consumed during the day.
2.4. Serum sample preparation
Preceding the first 24-HDR interview by approximately one week
(or two weeks in the Czech Republic), participants gave a non-fasted
blood sample, from which serum was immediately isolated, aliquoted,
and stored at −80 °C. Several sample preparation techniques that are
reported in the literature, such as immuno-affinity column separation,
salt-assisted liquid-liquid extraction, or general solid-phase extraction,
were not considered feasible due to the relatively low volumes of
EFCOVAL serum samples. As such, a protein precipitation technique
was applied, as described below, on a total of 61 Dutch, 58 Belgian, 40
Czech, 78 Norwegian, and 32 French serum samples.
Serum samples were thawed at 4 °C, briefly vortexed, then 50 µL
was transferred to a new polypropylene tube. To this, 100 µL of cold
acetonitrile containing 1% (v/v) formic acid was added, the mixture
was vortexed, then allowed to stand for one hour at 4 °C. These samples
were centrifuged at 10,000g for 10 min, then 120 µL of the supernatant
was transferred to an injection vial and evaporated to dryness under a
steady stream of nitrogen in a water bath at 40 °C. The residue was
dissolved by vortexing in 10 µL methanol containing 0.4% (v/v) formic
acid, then 30 µL of ultrapure water containing 0.4% (v/v) formic acid
was added and mixed, producing a dilution factor of 1. The used con-
sumable materials and reagents are detailed in Supplementary File S1.
2.5. Urine sample preparation
During each of the two days for which participants had been asked
for a 24-HDR, participants had collected their urine over the following
24-hour period. These urine samples were stored at −80 °C until use.
The sample preparation procedure followed a recently published ap-
proach (Breidbach, 2017), slightly adapted for aqueous samples, as
described below. A total of 62 (n= 31) Dutch, 96 (n= 59) Belgian, 79
(n = 40) Czech, and 76 (n = 58) Norwegian urine samples were suc-
cessfully assayed on multiple mycotoxins; urine samples from France
were not available.
After thawing at 4 °C, 500 µL of urine was added to 500 µL of ul-
trapure water containing 1% (v/v) formic acid, then 1 mL of ethyl
acetate was added, and mixed thoroughly by overhead shaking for one
hour. Next, 1 g of sodium sulfate was added, and shaken by hand for
one minute, then crystallized for 20 min. The samples were centrifuged
at 3000g for 3 min, then 320 µL of the organic phase was transferred to
an injection vial and evaporated to dryness under a steady stream of
nitrogen in a water bath at 40 °C. The residue was dissolved by vor-
texing in 40 µL methanol containing 0.4% (v/v) formic acid, then
120 µL of ultrapure water containing 0.4% (v/v) formic acid was added
and mixed, producing a dilution factor of 1.
Urinary osmolality was used to determine relative dilution factors
for urine samples. This was measured by a Model 3320 Osmometer
from Advanced Instruments, Inc. (Massachusetts, USA). Six-fold re-
plicate measurements of osmolality in control samples and calibrant
solutions returned standard deviations less than 1.5% of the observed
average. Therefore, samples were measured in duplicate, and the
average recorded osmolality was used for normalization of detected
mycotoxin concentrations. The used consumable materials and reagents
are detailed in Supplementary File S1.
2.6. UPLC-MS/MS And HRMS analysis
Analytical reference standards were not commercially available for
some metabolized forms of mycotoxins of interest. Therefore, phase I
metabolites aflatoxin Q1 (AFQ1), and monoacetoxyscirpenol (MAS), as
well as the phase II metabolites deoxynivalenol-3-glucuronide
(DON3GlcA) and deoxynivalenol-15-glucuronide (DON15GlcA) were
produced by incubating analytical standards with liver microsomes,
according to a previously described method (Yang et al., 2015; Yang
et al., 2017) (Supplementary File S2). The instrumental parameters
are detailed in Supplementary File S2. Observed mass transitions and
target-specific parameters are listed in Table 2.
The limit of quantification (LOQ) was set as the lowest concentra-
tion analytical standard observed above the limit of detection (LOD), in
turn, set at an extrapolation of the linear dose-response to three stan-
dard deviations above the mean background noise signal (Table 2).
Sample signals identified above LOQ were subsequently normalized
against internal standard signals to counter matrix effects, and in the
case of urine samples, further normalized by urinary dilution coeffi-
cients.
2.7. Mycotoxin grouping
Through each of the three measurement points, some mycotoxins
may be represented by various forms, which were detected in-
dividually. For example, deoxynivalenol-3-glucoside (DON3Glu) in the
food may be cleaved to DON in the gut and further metabolized to
DON15GlcA in the urine. Additionally, some co-produced mycotoxins
were grouped to account for unreported specificity of mycotoxin, con-
taminating the diet of the population. Hence, in addition to individual
mycotoxins, groups of related mycotoxins were used to facilitate direct
comparison between the three types of exposure measurement.
The group Aflatoxins includes AFB1, aflatoxin B2 (AFB2), aflatoxin
G1 (AFG1), aflatoxin G2 (AFG2), aflatoxin Q1 (AFQ1), and aflatoxin
K. De Ruyck, et al. Environment International 137 (2020) 105539
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B1-lysin (AFB1-Lys). The group Alternaria toxins includes altenuene,
altertoxin, alternariol methyl ether (AME), alternariol (AOH), tentoxin,
and tenuazonic acid (TA) (only AME, AOH, and TA were measured by
UPLC-MS/MS). The group Diacetoxyscirpenol includes diacetox-
yscirpenol (DAS), mono-acetoxyscirpenol (MAS), and neosolaniol
(NEO). The group Enniatins includes enniatin A, enniatin A1, enniatin B,
and enniatin B1 (EnB1) (only EnB1 was measured by LC-MS/MS). The
group Ergot alkaloids includes ergocornine (Eco), ergocristine (Ecr),
ergokryptine (Ek), ergometrine (Em), ergosine (Es), ergotamine (Et),
and their respective inin-epimers (Econ, Ecrn, Ekn, Emn, Esn, and Etn,
Table 2
LC-MS/MS parameters for targeted mycotoxin detection.








Patulin PAT 2.32 [M+H]+ 155.05 30 81.10 10 71.15 10 0.869 50 25
T-2 toxin tetraol T2(OH)4 2.49 [M+H]+ 299.15 30 175.15 18 0.507 1000 944
[M+NH4]+ 316.20 30 173.25 18
Nivalenol NIV 2.51 [M+H]+ 313.15 35 175.20 12 125.20 10 0.449 336 305
Deoxynivalenol-3-glucuronic
acid
DON-15-GlcA 2.84 [M−H]− 471.00 60 175.05 40 149.90 45 0.776
Deoxynivalenol-15-glucuronic
acid
DON-15-GlcA 3.06 [M−H]− 471.00 60 149.90 45 217.00 40 0.512
Deoxynivalenol-3-glucoside DON-3-G 3.21 [M+Na]+ 481.20 40 451.25 25 433.00 25 0.418 73 46
Deoxynivalenol DON 3.23 [M+H]+ 297.15 30 175.30 20 189.25 15 0.411 168 108
13C-deoxynivalenol (IS) 13C-DON 3.23 [M+H]+ 312.10 30 262.90
Ergometrine Em 3.42 [M+H]+ 325.60 30 223.00 20 265.00 18 0.883 99 60
Deepoxydeoxynivalenol DOM 4.05 [M+H]+ 281.15 30 109.25 9 137.30 9 0.798 168 96
Methyl ergometrine (IS) MeEm 4.13 [M+H]+ 340.20 30 208.25 27
Neosolaniol NEO 4.16 [M+NH4]+ 400.20 40 185.30 18 215.20 18 0.794 22 18
Ergometrinine Emn 4.18 [M+H]+ 325.60 30 223.00 20 265.00 18 0.269 99 83
Verrucarol VER 4.46 [M+H]+ 267.15 30 185.25 12 159.15 16 0.814 31 29
3-acetyl-deoxynivalenol 3AcDON 4.89 [M+H]+ 339.15 35 203.25 15 137.20 10 0.950 280 164
15-acetyl-deoxynivalenol 15AcDON 4.89 [M+H]+ 339.15 35 137.20 10 203.25 15 0.950 280 136
Aflatoxin B1-lysine adduct AFB1-Lys 5.40 [M+H]+ 457.30 30 394.20 20 310.90 33 0.034
Aflatoxin Q1 AFQ1 5.55 [M+H]+ 329.05 40 273.10 20 259.10 20 0.165
Aflatoxin G2 AFG2 5.56 [M+H]+ 331.10 40 245.10 30 285.10 25 0.981 3 1
Aflatoxin M1 AFM1 5.65 [M+H]+ 329.05 40 273.10 22 311.10 25 0.356 5 5
Ochratoxin alpha OTα 5.74 [M+H]+ 257.00 30 239.10 10 221.10 20 0.340 420 262
Aflatoxin G1 AFG1 5.99 [M+H]+ 329.05 40 243.10 25 283.05 25 0.442 9 1
Aflatoxin B2 AFB2 6.53 [M+H]+ 315.00 40 287.00 26 259.00 28 0.945 9 5
Tenuazonic acid TA 6.60 [M−H]− 196.10 55 139.00 20 112.00 24 0.517 250 180
Ergosinine Esn 6.75 [M+H]+ 548.10 30 276.90 23 319.90 20 0.758 889 99
Ergosine Es 6.99 [M+H]+ 548.10 30 276.90 23 319.90 20 0.698 209 99
Aflatoxin B1 AFB1 7.05 [M+H]+ 313.05 40 285.05 20 269.05 30 0.585 3 2
Diacetoxyscirpenol DAS 7.13 [M+NH4]+ 384.20 40 199.25 18 183.25 20 0.575 22 9
Ergotaminine Etn 7.21 [M+H]+ 582.10 30 277.00 23 297.00 23 0.023 296 99
Citrinin CIT 7.33 [M+H]+ 251.10 30 233.10 12 205.15 25 0.427 61 38
T-2 toxin triol T2(OH)3 7.36 [M+Na]+ 405.20 40 303.15 14 125.25 14 0.062 202 86
Ergotamine Et 7.40 [M+H]+ 582.10 30 277.00 23 268.00 23 0.050 296 99
Ergocornine Eco 7.43 [M+H]+ 561.50 35 267.90 20 347.90 20 0.204 296 99
Dihydro ergotamine (IS) DHEt 7.52 [M+H]+ 584.30 30 270.30 24
Zearalenone-14-glucuronic acid ZEN-14-GlcA 7.81 [M+H]+ 495.00 20 319.00 10 283.00 20 0.796
Ergokryptine Ek 8.48 [M+H]+ 576.10 30 268.00 23 305.00 23 0.073 296 99
Ergocristine Ecr 8.58 [M+H]+ 610.10 35 305.00 22 268.00 22 0.114 296 99
Ergocorninine Econ 8.60 [M−H2O + H]+ 544.10 35 276.95 25 304.90 25 0.383 99 50
Roquefortine C ROQ-C 8.80 [M+H]+ 390.20 40 193.30 25 322.15 20 0.537 22 10
13C-HT-2 toxin (IS) 13C-HT2 8.83 [M+H]+ 464.30 40 102.90 26
HT-2 toxin HT2 8.83 [M+NH4]+ 447.20 40 285.10 20 0.085 36 22
[M+Na]+ 442.25 40 185.14 11
Hydrolysed fumonisin B1 H-FB1 8.98 [M+H]+ 406.35 40 334.30 19 236.15 19 0.342 125 63
Alternariol AOH 9.02 [M+H]+ 259.05 30 213.10 25 241.10 25 0.487 61 15
Ergokryptinine Ekn 9.07 [M+H]+ 576.10 30 305.00 23 348.00 19 0.827 99 50
Ergocristinine Ecrn 9.24 [M+H]+ 610.10 35 305.00 22 325.00 22 0.401 296 99
Beta zearalenol β-ZEL 9.51 [M+H]+ 321.15 35 175.35 22 177.25 18 0.150 370 185
Fumonisin B1 FB1 9.55 [M+H]+ 722.40 40 352.20 20 334.40 20 0.445 81 58
T-2 toxin T2 9.87 [M+NH4]+ 489.20 40 245.30 25 0.741 13 8
[M+Na]+ 484.25 40 185.35 21
Alpha zearalenol αZEL 10.39 [M+H]+ 321.15 35 177.05 17 175.15 22 0.221 124 75
Zearalanone ZAN 10.47 [M+H]+ 321.15 35 189.20 17 187.20 22 0.593 125 119
Fumonisin B3 FB3 10.56 [M+H]+ 706.40 40 336.20 30 354.45 28 0.579 124 48
Zearalenone ZEN 10.71 [M+H]+ 319.15 35 187.20 17 185.20 19 0.314 101 61
Sterigmatocystin STE 11.09 [M+H]+ 325.05 40 281.10 35 310.05 22 0.904 5 3
Ochratoxin A OTA 11.10 [M+H]+ 404.10 40 239.10 22 221.10 35 0.456 11 6
13C-ochratoxin A (IS) 13C-OTA 11.10 [M+H]+ 422.00 40 377.00 20
Alternariol methyl ether AME 11.19 [M+H]+ 273.10 30 258.10 22 230.10 28 0.835 63 37
Fumonisin B2 FB2 11.28 [M+H]+ 706.40 40 336.20 32 354.30 35 0.406 134 86
Enniatin B EnB 11.85 [M+H]+ 640.40 30 196.25 21 214.25 26 0.474 1000 570
Legend: retention time (RT), mass to charge ratios (m/z) for precursor ion and two fragment ions (targets used for internal standards (IS) only recorded one dominant
transition), as well as cone voltage (V) and collision energies (C.E.) (eV) required for optimal signal strength; LOD (limit of detection) and LOQ (limit of quanti-
fication)
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respectively). The group Fumonisins includes fumonisin B1 (FB1), fu-
monisin B2 (FB2), and fumonisin B3 (FB3). The group Ochratoxins in-
cludes ochratoxin A (OTA) and ochratoxin α (OTα). The group T2 &
HT2 includes HT-2 toxin (HT2), T-2 toxin (T2), T-2 toxin triol (T2OH3)
and T-2 toxin tetraol (T2OH4). The group Type-B Trichothecenes in-
cludes 3-acetyl deoxynivalenol (3AcDON), 15-acetyl deoxynivalenol
(15AcDON), deoxynivalenol (DON), DON3Glu, deepoxydeoxynivalenol
(DOM), deoxynivalenol-3-glucuronide (DON3GlcA), deoxynivalenol-
15-glucuronide (DON15GlcA), fusarenone X (F-X), and nivalenol (NIV).
The group Zearalenone includes alpha zearalenol (αZEL), beta zear-
alenol (βZEL), zearalanone (ZAN), and zearalenone (ZEN).
2.8. Statistical comparison between mycotoxin exposure measurements
The software package R 3.5.0 (Vienna, Austria) was used for sta-
tistical analysis. The percentage agreement in recurring positive or
negative detections between measures, as well as Cohen's kappa, were
calculated to describe agreement between time points or between types
of measurement in terms of positive/negative screening. Cohen's kappa
was interpreted according to the guidelines published by Landis and
Koch (1977). The number of intersecting positive detections was
counted, and their levels were compared by percentage coefficient of
variance for measurements of the same type, or Spearman’s test for
correlation between different types of measurements. Finally, after
treating all negative detections as zero, Spearman’s test for correlation
was applied to compare serum, mean 24-HDR, and mean urine against
each other.
For quantitative comparisons, the 24-HDR dataset was used as ‘ng
per day per kilogram bodyweight’, while serum and urinary mycotoxin
concentrations were expressed as ‘ng/L’. Generalized linear models
were constructed for multivariate analysis on log-transformed con-
centration data, in order to satisfy assumptions of Gaussian distribution.
Cohen’s kappa was also applied to test for agreement over individuals
exceeding median mycotoxin concentrations.
Exposures to groups of mycotoxins were assessed by Kruskal-Wallis
H test for significant differences between different age brackets, body
mass index (BMI), or geographic regions; significant differences be-
tween genders was assessed by Wilcoxon signed-rank test. Null hy-
potheses were rejected, and association considered significant at (*)
p < 0.05; (**) p < 0.01; (***) p < 0.001.
3. Results
3.1. Mycotoxin prevalence
According to their reported diet, all of the EFCOVAL cohort’s 600
individuals were exposed to dietary mycotoxins during the two sam-
pling days, as listed in Table 3. Of particular note, the carcinogen AFB1,
along with other aflatoxins, and DON, AcDON, OTA, and ZEN were
calculated to be present in at least one 24-HDR for all 600 individuals;
OTA was present in every individual’s diet on both days. Individuals
with particularly high exposures to HT2, PAT, STE, T2, or the groups
Aflatoxins, Diacetoxyscirpenol, Ergot alkaloids, Fumonisins, Ochratoxin A,
and Zearalenone, were all found to exceed the tolerable daily intakes
(TDI) per kg body weight.
Serum measurements were able to detect at least one mycotoxin in
261 (97%) out of 268 samples, and 187 (99%) individuals out of 188
were observed to have mycotoxins in their urine, as listed in Table 4.
The most prevalent groups were Aflatoxins (serum 57%; urine 51%),
Ergot Alkaloids (serum 43%; urine 56%), Fumonisins (serum 42%; urine
40%), Ochratoxins (serum 42%; 48%), and Type B Trichothecenes (serum
42%; urine 52%). Additionally, PAT (70%) was frequently detected in
serum, but was not detected in urine.
3.2. Co-exposure to multiple mycotoxins
As shown in Fig. 1, analysis of 24-HDR determined co-exposure to a
minimum of 4 different mycotoxins, with one individual reporting a
day’s food intake up to 34 different mycotoxins. The most common
number of calculated co-exposures from dietary intake in a single day
was 12 mycotoxins. Blood samples were observed to contain up to 12
mycotoxins, with 4 co-exposures in 20% of samples being most
common. Only 5% of the population tested positive for only one my-
cotoxin. In urine samples, up to 13 individual targets were co-detected,
with a mode of 5 co-detections in 18% of samples, and 4% returning a
single detection, only.
Grouping the mycotoxins, as described above, resulted in 8 to 13 co-
exposed groups in the dietary analysis, while blood and urine were
found contaminated by up to 9 or 8 groups, with 4 or 5 groups being
most common, respectively. Among samples that tested positive for at
least one mycotoxin, 8% of blood and 4% of urine samples were found
contaminated with only 1 group of mycotoxins.
3.3. Demographic variables and mycotoxin exposure
As illustrated in Fig. 2, distributions of detected exposure levels for
most groups of mycotoxins were found by Kruskal-Wallis H test to be
significantly different between countries. Further, several mycotoxin
groups (Aflatoxins, DAS, Ergot Alkaloids, Ochratoxins, and T2 & HT2)
were found to significantly differ between countries according to all
three measurement types. Nevertheless, few consistent patterns of
geographic distribution were observed between measurement types,
and the frequent occurrence of outlier data points more than two in-
terquartile ranges away from the median indicate high degrees of
variability in detected exposure levels even within countries.
As depicted in Supplementary File S3, exposures to groups of
mycotoxins were not widely correlated with participants’ age, nor body
mass index (BMI) according to measurements in biological fluids.
Kruskal-Wallis H tests identified significant differences in the 24-HDR
calculated exposures for some mycotoxin groups and decennial age
strata (Aflatoxins, Enniatins, and Ochratoxins), BMI (Aflatoxins, Alter-
naria Toxins, DAS, Ochratoxins, PAT, T2 & HT2, Type B Trichothecenes,
and Zearalenone), and gender (Aflatoxins, Alternaria Toxins, Ochratoxins,
PAT, STE, and Type B Trichothecenes). However, these observations
were not consistent across different measurement types.
3.4. Repeated 24-HDR mycotoxin exposure estimates (2× 24-HDR)
Table 5 represents correlations between mycotoxin exposures as-
sessed on two different time points for the EFCOVAL-individuals who
completed a 24-HDR on two occasions. Significant correlations for the
two 24-HDR were found by Spearman’s test for almost all individual
and grouped mycotoxins, excepting only CIT, DAS, Ek, PAT, T2, TA,
and all individual or grouped members of Fumonisins and Zearalenone
(Table 5).
Supplementary analyses were run to investigate agreement for
mycotoxin detection between these two different time points. At least
99% agreement between detection rates at both 24-HDR time points
was observed for the mycotoxins AFB1, OTA, PAT, DON, and ZEN, as
well as the groups Aflatoxins, Ochratoxins, Type B Trichothecenes, and
Zearalenone (Supplementary Table S3). Nevertheless, screening de-
tection rates were in less than moderate agreement (Cohen’s Κ ≤ 0.4,
Table 5). Noteworthy, when one measurement has little to no variation
(e.g., all subjects scoring positive for the mycotoxin), the agreement
corrected for chance (Κ) is considered to be 0, or close to 0, and will
require many successive ratings in order to mitigate the chance variable
and indicate correlation. This explains the low Κ-values for mycotoxins,
where the agreement is close to 100%.
The amounts calculated to contaminate each individual’s diet were
found to vary considerably depending on the mycotoxin, with average
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Table 3
Dietary mycotoxin exposure estimates as the mean of two 24-hour dietary recall surveys, recorded one month apart.
Mycotoxins n = 600 Min Q1 Median Q3 Max Min Q1 Median Q3 Max TDI
Detections (%) Mean ng intake per day ng intake per kg body weight (b.w.) ng/kg b.w./day
Aflatoxins Group Total 600 (100.0) 9.12 256 647 1330 9520 0.140 3.39 8.70 18.5 107 n.a.
AFB1 600 (100.0) 1.75 46.4 429 911 5210 0.027 0.584 5.61 13.6 81.4 n.a.
AFB2 600 (100.0) 0.413 15.3 23.0 35.0 473 0.008 0.198 0.317 0.483 5.32 n.a.
AFG1 600 (100.0) 1.12 15.8 24.3 35.2 1060 0.015 0.209 0.321 0.488 16.6 n.a.
AFG2 600 (100.0) 0.957 15.4 23.7 35.8 129 0.014 0.197 0.322 0.499 2.02 n.a.
AFM1 588 (98.0) 0.02 0.749 1.98 14.1 433 2.2e−4 0.010 0.027 0.178 6.10 n.a.
Alternaria Toxins Group Total 598 (99.7) 179 4770 7980 12,100 57,400 2.41 66.1 109 162 787 n.a.
Altenuene 598 (99.7) 9.00 340 645 1010 4150 0.108 4.39 8.52 14.0 57.5 n.a.
AOH 598 (99.7) 13.0 405 699 1220 8640 0.161 5.60 9.78 16.6 97.2 n.a.
AME 598 (99.7) 4.73 114 218 521 8300 0.061 1.57 2.98 6.93 93.4 n.a.
Altertoxin I 554 (92.3) 5.00 565 1110 1630 4150 0.069 7.78 14.7 22.0 70.6 n.a.
Tentoxin 597 (99.5) 1.20 171 328 561 6060 0.014 2.24 4.37 7.79 94.7 n.a.
TA 598 (99.7) 17.8 2360 397 6440 39,700 0.239 32.8 54.8 86.6 557 n.a.
Beauvericin 264 (44.0) 0.30 5.50 11.0 20.8 135 0.004 0.070 0.161 0.307 1.44 n.a.
CIT 7 (1.2) 2.50 26.6 30.2 30.5 84.0 0.039 0.329 0.356 0.391 1.45 n.a.
DAS 6 (1.0) 17.0 586 1130 2040 8910 0.315 8.00 15.3 27.0 97.4 60
Enniatins Group Total 330 (55.0) 4.38 130 302 972 281,000 0.055 1.70 4.39 13.0 5160 n.a.
Enniatin A 330 (55.0) 0.30 7.93 18.9 40.3 234,000 0.004 0.113 0.261 0.565 4290 n.a.
Enniatin A1 330 (55.0) 1.53 39.8 96.2 207 25,000 0.019 0.565 1.35 2.76 459 n.a.
Enniatin B 330 (55.0) 0.60 17.9 43.1 227 43,600 0.008 0.236 0.639 2.96 588 n.a.
EnB1 330 (55.0) 1.95 55.4 126 381 16,100 0.025 0.745 1.85 5.10 244 n.a.
Ergot Alkaloids Group Total 388 (64.7) 60 1170 3070 10,200 55,700 0.698 15.2 41.4 135 731 600
Eco 313 (52.1) 5.00 84.0 200 904 9280 0.058 1.19 2.96 13.2 118 600
Econ 290 (48.3) 4.44 60.0 138 442 3750 0.058 0.786 1.88 6.14 42.2 600
Ecr 388 (64.7) 5.00 122 500 1500 12,400 0.058 1.56 6.91 21.2 168 600
Ecrn 290 (48.3) 4.44 60.0 142 527 3750 0.058 0.786 2.02 6.68 42.2 600
Ek + Ekn 148 (24.7) 250 800 1670 3290 12,400 2.87 10.0 24.0 49.4 168 600
Em 274 (45.7) 5.00 68.0 155 740 9280 0.058 0.971 2.22 10.1 118 600
Emn 251 (41.8) 3.83 45.0 106 500 4690 0.050 0.600 1.44 6.72 52.7 600
Es 313 (52.2) 5.00 68.3 200 905 9280 0.058 0.981 2.71 12.1 118 600
Esn 290 (48.3) 5.00 60.0 149 600 3750 0.058 0.786 2.10 8.15 42.2 600
Et 360 (60.0) 5.00 115 500 1600 14,300 0.058 1.47 6.98 22.9 232 600
Etn 251 (41.8) 5.00 48.0 117 427 3750 0.058 0.646 1.47 6.02 42.2 600
Fumonisins Group Total 572 (95.3) 6.00 1680 3270 6230 247,000 0.095 23.1 43.7 85.4 2450 2000
FB1 571 (95.2) 3.00 778 1540 2960 201,000 0.048 10.8 20.7 39.8 1990 2000
FB2 571 (95.2) 3.00 662 1300 2160 32,200 0.048 8.82 17.5 29.6 319 2000
FB3 225 (37.5) 13.3 131 499 1130 13,300 0.164 1.99 6.67 15.0 132 2000
OTA 600 (100.0) 26.9 237 401 619 4850 0.387 3.07 5.30 8.65 76.3 14
PAT 311 (51.8) 27.5 1430 2180 3250 393,000 0.388 19.1 29.2 45.2 6150 400
STE 68 (11.3) 37.5 125 191 282 1280 0.583 1.84 2.47 4.07 11.3 n.a.
T2 & HT2 Group Total 591 (98.5) 2.42 1100 2220 4040 26,500 0.029 14.5 30.6 55.4 290 60
HT2 591 (98.5) 1.27 470 980 1900 13,200 0.015 6.38 13.5 25.8 144 60
T2 589 (98.2) 1.15 187 465 1500 13,200 0.014 2.55 6.41 20.1 144 60
Type B
Trichothecenes Group Total 600 (100.0) 279 9680 17,000 27,700 89,000 3.76 138 234 234 973 1000
3AcDON 600 (100.0) 18.0 723 1460 2370 10,100 0.191 9.79 19.5 31.9 113 1000
15AcDON 600 (100.0) 18.0 748 1450 2310 7290 0.191 9.84 19.4 31.8 95.4 1000
DON 600 (100.0) 42.0 5770 11,400 20,800 86,900 0.566 79.7 155 274 950 1000
DON3Glu 124 (20.7) 4.00 1290 2910 4810 15,300 0.067 17.8 40.0 63.5 237 1000
F-X 156 (26.0) 6.38 330 538 922 2913 0.093 4.32 7.43 11.8 32.8 1000
NIV 596 (99.3) 7.30 471 816 1360 5180 0.089 6.42 11.1 19.6 71.0 1000
Zearalenone Group Total 600 (100.0) 28.0 630 1070 2760 39,100 0.377 8.70 15.0 36.6 639 250
αZEL 41 (6.8) 0.50 16.0 25.0 62.5 481 0.008 0.275 0.347 0.801 6.25 250
βZEL 41 (6.8) 1.52 25.0 40.0 62.5 481 0.025 0.342 0.610 0.864 6.25 250
ZAN 11 (1.8) 39.0 47.4 54.6 66.0 94.8 0.486 0.743 0.841 1.02 1.30 250
ZEN 600 (100.0) 28.0 564 951 2330 38,500 0.377 7.76 13.1 30.1 629 250
Legend: Group Totals may include non-specifically reported mycotoxin contaminants from the EFSA database. For mycotoxins both with published and no described
tolerable daily intakes (TDI), outstanding values are in grey-bold. n.a.: no TDIs are available or described. Mycotoxin abbreviations are as follows: 3-acetyl deox-
ynivalenol (3AcDON); 15-acetyl deoxynivalenol (15AcDON); aflatoxin B1 (AFB1); aflatoxin B2 (AFB2); aflatoxin G1 (AFG1); aflatoxin G2 (AFG2); aflatoxin M1
(AFM1); alpha zearalenol (αZEL); alternariol (AOH); alternariol methyl ether (AME); beta zearalenol (βZEL); citrinin (CIT); creatinine (CTN); deepoxydeoxynivalenol
(DOM); deoxynivalenol (DON); deoxynivalenol-3-glucoside (DON3Glu); diacetoxyscirpenol (DAS); dihydroergotamine (DHEt); enniatin B1 (EnB1); ergocornine
(Eco); ergocristine (Ecr); ergokryptine (Ek); ergometrine (Em); ergosine (Es); ergotamine (Et); and their respective epimers (Econ; Ecrn; Ekn; Emn; Esn; and Etn;
respectively); fumonisin B1 (FB1); fumonisin B2 (FB2); fumonisin B3 (FB3); fusarenone X (F-X); HT-2 toxin (HT2); methylergometrine (MeEm); neosolaniol (NEO);
nivalenol (NIV); ochratoxin A (OTA); ochratoxin α (OTα); patulin (PAT); roquefortine C (ROQ-C); sterigmatocystin (STE); T-2 toxin (T2); T-2 toxin tetraol (T2OH4);
T-2 toxin triol (T2OH3); verrucarol (VER); zearalanone (ZAN); zearalenone (ZEN).
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Table 4
Mycotoxin detections in serum samples obtained one or two weeks prior to the first or two pooled 24-hour urine collections, separated by one month are detailed. All
concentrations are in ng/L.
Mycotoxins n = 268 Serum n = 188 Mean of Two 24hr Urine Collections
Detections (%) Min Q1 Median Q3 Max Detections (%) Min Q1 Median Q3 Max
Aflatoxins Group Total 154 (57.2) 0.2 16.5 37.9 83.8 8720 95 (50.5) 1e-2 11.7 33.6 155 4730
AFB1 39 (14.5) 0.1 1.50 9.30 43.4 141 20 (10.6) 1e-2 0.3 5.5 73.6 236
AFB2 73 (27.1) 1.3 17.5 32.7 62.6 8710 44 (23.4) 1.8 11.7 25.8 140 703
AFG1 7 (2.6) 3.7 10.3 13.2 122 393 2 (1.1) 23.9 36.8 49.7 62.6 75.4
AFG2 44 (16.4) 3.5 23.8 63.7 88.5 256 21 (11.2) 1.5 8.2 20.2 53.4 2580
AFM1 55 (20.4) 0.7 5.3 12.5 58.5 172 33 (17.6) 0.4 10.4 21.5 550 4730
Alternaria Toxins Group Total 0 (0.0) n.a. n.a. n.a. n.a. n.a. 53 (28.2) 25.0 1860 4040 10,200 28,500
AME 0 (0.0) n.a. n.a. n.a. n.a. n.a. 14 (7.4) 134 5430 16,400 20,100 22,400
AOH 0 (0.0) n.a. n.a. n.a. n.a. n.a. 14 (7.4) 25.0 319 596 972 1570
TA 0 (0.0) n.a. n.a. n.a. n.a. n.a. 39 (20.7) 154 2180 3500 6500 28,500
Citrinin 39 (14.5) 65.1 131 383 9370 59,400 27 (14.4) 60.2 186 618 999 8470
Diacetoxyscirpenol Group Total 82 (30.5) 0.5 9.8 29.9 123 7940 36 (19.1) 0.3 71.4 132 292 3390
DAS 61 (22.7) 2.7 13.8 69.7 203 7940 25 (13.3) 4.7 80.8 130 184 504
NEO 24 (8.9) 0.5 1.5 5.2 20.9 86.3 12 (6.4) 0.3 3.1 168 1550 3390
EnB1 0 (0.0) n.a. n.a. n.a. n.a. n.a. 81 (43.1) 296 844 1660 7590 17,900
Ergot Alkaloids Group Total 116 (43.1) 3.5 30.1 63.0 155 3240 106 (56.4) 0.1 37.2 191 942 31,100
Eco 14 (5.2) 66.6 86.9 158 534 2460 16 (8.5) 16.8 38.9 70.7 436 868
Econ 38 (14.1) 3.5 27.4 44.4 70.7 787 22 (11.7) 9.6 50.1 74.8 405 1440
Ecr 19 (7.1) 44.8 73.7 126 163 531 14 (7.4) 16.4 59.2 121 515 1100
Ecrn 23 (8.6) 7.2 12.1 14.9 18.2 111 18 (9.6) 6.5 14.7 139 752 1250
Ek 4 (1.5) 11.8 62.8 81.6 84.7 88.9 9 (4.8) 5.4 305 381 626 1090
Ekn 22 (8.2) 13.3 27.7 46.4 127 431 16 (8.5) 14.4 58.7 482 703 1600
Em 12 (4.5) 10.7 21.2 26.5 76.5 439 6 (3.2) 15.5 71.5 637 1570 2530
Emn 19 (17.1) 40.9 59.5 72.6 109 629 10 (5.3) 9.0 1210 5100 9240 29,700
Es 32 (11.9) 6.2 7.9 10.1 27.8 735 10 (5.3) 2.1 7.5 19.3 99 990
Esn 30 (11.1) 25.5 30.4 36.6 56.8 468 17 (9.0) 11.1 18.2 33.6 165 3880
Et 14 (5.2) 27.4 34.1 44.3 57.5 1400 9 (4.8) 0.1 24.7 45.0 104 990
Etn 1 (0.4) n.a. n.a. 61.2 n.a. n.a. 10 (5.3) 8.1 42.8 75.4 119 236
Fumonisins Group Total 113 (42.0) 683 4370 5370 9250 84,100 76 (40.4) 8.6 773 2770 6200 40,300
FB1 80 (29.7) 1070 4280 4990 7110 84,100 49 (26.0) 8.6 1350 3230 5430 23,900
FB2 43 (16.0) 683 4680 5290 5750 31,100 35 (18.6) 38.7 452 2790 5060 25,200
FB3 14 (5.2) 468 1050 1180 3340 43,000 6 (3.2) 915 1190 3460 7190 17,100
Ochratoxins Group Total 113 (42.0) 81.1 230 548 985 167,000 90 (47.9) 0.8 477 5820 18,700 1,610,000
OTA 104 (38.7) 68.1 210 454 770 16,500 76 (40.4) 0.8 210 1640 16,100 1,610,000
OTα 13 (4.8) 3520 4640 29,300 70,800 167,000 48 (25.5) 1.6 1510 3820 12,400 807,000
PAT 187 (69.5) 0.1 37.2 191 942 31,100 0 (0.0)
ROQ-C 64 (23.8) 2.3 4.3 5.3 10.1 300 13 (6.9) 2.1 3.0 9.4 1810 39,800
STE 24 (8.9) 15.4 20.0 61.3 315 420 30 (16.0) 4.7 51.5 2020 3670 8280
T2 & HT2 Group Total 98 (36.4) 20.3 55.5 93.9 793 19,200 56 (29.8) 6e-2 44.4 93.5 785 39,600
HT2 38 (14.1) 20.3 41.0 873 2440 19,200 12 (6.4) 30.0 54.6 484 1090 4660
T2 68 (25.3) 36.0 54.3 79.1 151 3330 41 (21.8) 6e-2 36.2 55.8 94.7 779
T2OH3 0 (0.0) n.a. n.a. n.a. n.a. n.a. 2 (1.1) 1020 10,700 20,300 30,000 39,600
T2OH4 0 (0.0) n.a. n.a. n.a. n.a. n.a. 8 (4.3) 703 17,400 24,400 26,700 37,100
Type B
Trichothecenes Group Total 113 (42.0) 4.7 230 645 2350 768,000 97 (51.6) 7.5 338 3490 15,600 82,100
AcDON 22 (8.2) 4.7 27.4 41.1 53.9 1820 44 (23.4) 6.2 104 12,700 21,800 56,900
DOM 18 (6.7) 378 712 1210 2240 313,000 12 (10.1) 75.6 763 3410 9730 32,700
DON 38 (14.1) 9.2 70.4 223 431 1390 46 (24.5) 1.4 224 494 3700 9070
DON3Glu 26 (9.7) 201 286 483 895 10,500 12 (6.4) 996 1650 2130 2800 37,200
F-X 14 (5.2) 99.0 708 876 1180 15,100 0 (0.0) n.a. n.a. n.a. n.a. n.a.
NIV 22 (8.2) 2710 5340 8090 31,400 454,000 6 (3.2) 2660 7410 9960 17,500 19,600
VER 0 (0.0) n.a. n.a. n.a. n.a. n.a. 4 (2.1) 1.6 2.5 2.8 3.3 4.7
Zearalenone Group Total 81 (30.1) 3.9 10,700 20,300 37,600 266,000 52 (27.7) 5.2 3800 13,800 29,700 501,000
αZEL 36 (13.3) 11,900 30,200 36,100 47,200 175,000 17 (9.0) 549 19,200 27,800 50,900 501,000
βZEL 46 (17.1) 236 10,100 12,000 14,300 256,000 34 (18.1) 27.6 4860 9070 20,600 116,000
ZAN 0 (0.0) n.a. n.a. n.a. n.a. n.a. 3 (1.6) 2870 14,700 26,500 61,000 95,400
ZEN 5 (1.9) 3.9 125 157 266 9890 6 (3.2) 5.19 28.0 769 2110 2950
Legend: Mycotoxin abbreviations are as follows: 3-acetyl deoxynivalenol (3AcDON); 15-acetyl deoxynivalenol (15AcDON); aflatoxin B1 (AFB1); aflatoxin B2 (AFB2);
aflatoxin G1 (AFG1); aflatoxin G2 (AFG2); aflatoxin M1 (AFM1); alpha zearalenol (αZEL); alternariol (AOH); alternariol methyl ether (AME); beta zearalenol (βZEL);
citrinin (CIT); creatinine (CTN); deepoxydeoxynivalenol (DOM); deoxynivalenol (DON); deoxynivalenol-3-glucoside (DON3Glu); diacetoxyscirpenol (DAS); dihy-
droergotamine (DHEt); enniatin B1 (EnB1); ergocornine (Eco); ergocristine (Ecr); ergokryptine (Ek); ergometrine (Em); ergosine (Es); ergotamine (Et); and their
respective epimers (Econ; Ecrn; Ekn; Emn; Esn; and Etn; respectively); fumonisin B1 (FB1); fumonisin B2 (FB2); fumonisin B3 (FB3); fusarenone X (F-X); HT-2 toxin
(HT2); methylergometrine (MeEm); neosolaniol (NEO); nivalenol (NIV); ochratoxin A (OTA); ochratoxin α (OTα); patulin (PAT); roquefortine C (ROQ-C); ster-
igmatocystin (STE); T-2 toxin (T2); T-2 toxin tetraol (T2OH4); T-2 toxin triol (T2OH3); verrucarol (VER); zearalanone (ZAN); zearalenone (ZEN).
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coefficients of variance ranging from 31% for STE to 82% for T2.
Nevertheless, incidences of concentrations above the median were
moderately to strongly associated (0.6 ≤ Κ < 0.8) for AFB1 (0.61),
Econ (0.63), Ecrn (0.63), Es (0.64), Esn (0.72), and βZEL (0.62)
(Supplementary File S4).
3.5. Urinary mycotoxin detections in repeated sampling (2× 24HR Urine)
Mycotoxins were determined in two separately pooled, 24-hour
collection urine samples from 125 individuals, obtained at least one
month apart. Detection rates across the two time-points were evaluated
by Cohen’s Κ and moderate agreements (0.4 < Κ≤ 0.6) were observed
for Esn, OTA, and ROQ-C as listed in Table 5. However, less than half of
all mycotoxins were found to have better than 90% agreement in terms
of screening between the two time points. On average, only 7.4% of
individuals tested positive for the same groups of mycotoxins in both
urine samples. Further, the mean percentage coefficient of variance
between the concentrations detected at each time point were found to
exceed 50% for almost all mycotoxins, except βZEL (40%), AOH (16%),
DON (33%), and T2 (37%) (Supplementary File S4). Incidence of
concentrations above the median were strongly associated (Κ = 0.81)
between time points for EnB1, and moderately associated for the groups
Aflatoxins and T2 & HT2, as well as T2 individually (Supplementary
File S4). Nevertheless, counting negative detections as 0, and applying
Spearman’s test identified αZEL, AFG2, AFM1, EnB1, Es, Esn, OTA,
ROQ-C, T2, 15AcDON, and DON as significantly correlated between
time points (Table 5).
3.6. Comparison of mycotoxin detections between 24-HDR and 24-hour
pooled urine collection (24-HDR VS 24HR Urine)
Participants collected urine for 24 h before submitting a 24-HDR
covering that day’s diet. Detection rates of grouped mycotoxins were
only in slight or negative agreement, with Cohen’s Κ calculated at less
than 0.2 for all mycotoxins (Table 5). There was at least 80% agreement
in detection rates between the two measurement types for the in-
dividual mycotoxins CIT, FB2, STE, DON3Glu, αZEL, βZEL, and ZAN,
though the average agreement for all mycotoxins was only 33%. For
quantitative analyses, some significant correlations were found for
AFG1 (0.14), AFG2 (0.12), HT2 (0.12), DON (0.16) (Table 5). However,
applying Spearman’s test to intersecting positive detections only, there
was no significant positive correlation observed between actual levels
measured of any individual or grouped mycotoxins.
For 188 participants, mycotoxin detections at up to two time points
could be averaged, and the mean 24-HDR concentrations compared to
the mean urine concentrations, as listed in Table 6. The two types of
measurements did not agree more than slightly (Κ≤ 0.2) on detection
rates according to Cohen’s K, despite high percentage agreement for CIT
(84%), FB3 (80%), αZEL (85%), and ZAN (96%) (Table 6). Spearman’s
test did not find any significant positive correlation between any de-
tected levels (Table 6).
3.7. Comparison of mycotoxin detections between mean 24-HDR and serum
The mycotoxin detection profiles obtained from 268 individuals'
serum samples were compared with 24-HDR-mycotoxin exposure esti-
mates, as listed in Table 6. Rates of detection agreed slightly or nega-
tively (Κ< 0.1), according to Cohen's Κ for any mycotoxins, except for
STE (Κ = 0.12), which also had 81% agreement between the mea-
surement types (Table 6). Further, Spearman’s test found significant
correlations for Et (ρ = 0.15), OTA (ρ = 0.13), STE (ρ = 0.13), and
AcDON (ρ = 0.15). After grouping mycotoxins, detected levels were not
found by Spearman’s test to be significantly positively associated
(p < 0.05), nor was the incidence of levels above the median found by
Cohen's kappa to agree between mean 24-HDR and serum
(Supplementary File S5).
Fig. 1. Kernel density estimate of the
number of individual mycotoxins de-
tected together in individual samples ac-
cording to three methods of assessment:
24-HDR; 24-hour pooled urine and
serum. Legend: The density of co-ex-
posure levels within the population is
expressed as a decimal fraction for direct
comparability between measurement
types.
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3.8. Comparison of mycotoxin detections between serum and urine (serum
VS mean 24HR urine)
Levels of mycotoxins in 147 serum samples, which were taken on
average one or two weeks prior to the first urine collections, were
compared to the average in urine from the same individuals, as listed in
Table 6. Comparing detection rates between the two biological sample
types yielded moderate associations (0.4 < Κ≤ 0.6) for the individual
mycotoxins AFB2, AFG1, AFG2, AFM1, DAS, NEO, Ecrn, Esn, FB1, T2,
βZEL, and ZEN, as well as the groups Aflatoxins, Diacetoxyscirpenol,
Fumonisins, and T2 & HT2 (Table 6). All of the individual mycotoxins
that scored highly on Cohen’s Κ were also found to have > 80%
agreement between serum and urine detection rates. Spearman’s test
found significant positive correlations (0.18 ≤ ρ ≤ 0.58) for almost all
individual and grouped mycotoxins (Table 6). Most notably excepted
was OTA and the Ochratoxins group, though OTα (ρ = 0.31) was cor-
related. Other individual mycotoxins for which significant correlations
were not found included CIT, Eco, Ekn, Em, Emn, Etn, and DON3Glu.
Total detected amounts of the grouped mycotoxins were found by
Spearman’s test to be significantly correlated between blood and urine
samples for the groups Aflatoxins (Spearman’s rho (ρ) = 0.32),
Fumonisins (ρ = 0.32), Ochratoxins (ρ = 0.43), and Type B
Trichothecenes (ρ = 0.66) (Supplementary File S5). Moderate and
substantial agreements on incidence of levels above the median were
calculated by Cohen’s kappa for the groups Type B Trichothecenes
(Κ = 0.57) and Zearalenone (Κ= 0.67), respectively (Supplementary
File S5).
4. Discussion
Mycotoxin contamination is a ubiquitous problem, which is con-
firmed in the present study by three different methods. Accurate as-
sessments of the contamination level are vital to understanding how
dietary mycotoxins may affect individual health. Unfortunately, the
three different measurements illustrate the relative outcome dis-
crepancies of these measures, either individually or taken together, for
determining dietary mycotoxin exposure in the individual.
4.1. Demographic variables and mycotoxin exposure
The significant differences identified between grouped mycotoxin
exposure levels in different countries may be influenced by a wide
range of factors. Distinct dietary habits may be investigated to de-
termine if specific regional foods are vectors for mycotoxin exposure.
Additionally, this may indicate differences in the presence of myco-
toxigenic fungi and subsequent mycotoxin expression due to environ-
mental characteristics (Van Der Fels-Klerx et al., 2012). The colder
climate of Norway also affects local agricultural production. The import
of agricultural products extends the supply chain, which potentially
increases the risk of mycotoxin contamination (Magan and Aldred,
2007). Interestingly, biological sampling (serum and urine) did not
differentiate Norwegians, leading to two possible hypotheses: either the
distribution of mycotoxins in FoodEx1 standard classifications of food
items was not accurately described prior to assessing dietary mycotoxin
levels, or the mycotoxins were not consumed on the days when biolo-
gical samples were taken. The significantly higher total mycotoxin le-
vels of Belgian urine and French serum samples may be affected by
Fig. 2. Comparison of mycotoxin groups’ exposure concentrations detected in samples from each country. Legend: The mycotoxin exposure is annotated as the
exposure levels of the mycotoxin groups. Significantly different distributions were identified by the Kruskal-Wallis H test. The probability cut-offs for significantly
independent groups were set at (*) p < 0.05; (**) p < 0.01; (***) p < 0.001. The boxplots of mycotoxin concentrations illustrate the interquartile range as a box,
with a black bar indicating the median, and dashed extensions to the lowest and highest detected concentrations, excepting outliers further than 1.5 interquartile
ranges above the upper quartile or below the lower quartile. Additionally, a scatterplot alongside serves to illustrate sample size, patterns of distribution, and outliers.
Each mycotoxin group was assessed by Kruskal-Wallis H test for significant differences between demographic groups; significant differences between genders was
assessed by Wilcoxon signed-rank test. Null hypotheses were rejected, and association considered significant at (*) p < 0.05; (**) p < 0.01; (***) p < 0.001; (****)
p < 0.0001.
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Table 5
Statistical comparisons between repeated mycotoxin exposure measurements taken one month apart, either from 24-hour dietary recall (24-HDR) surveys, or in
pooled 24-hour urine collections. 24-HDR was compared to 24-hour urine from the same day; each timepoint was compared separately.
Mycotoxins 2x 24-HDR, n = 595 2x 24hr Urine, n = 125 24-HDR vs 24hr Urine, n = 313
K % agr ρ +ve (%) K % agr ρ +ve (%) K % agr ρ +ve (%)
Aflatoxins Group total 0 99.8 0.69*** 594 (99.8) −0.01 59.2 0.08 9 (7.2) 0 33.4 0.12 103 (32.9)
AFB1 0 99.5 0.73*** 592 (99.5) −0.05 88.0 −0.05 0 (0.0) 0 7.2 −0.09 20 (6.4)
AFB2 −0.01 98.5 0.31*** 586 (98.5) 0.11 81.6 0.12 3 (2.4) 0 16.8 0.09 47 (15.0)
AFG1 −0.01 98.5 0.81*** 586 (98.5) 0 98.4 n.a. 0 (0.0) 0 12.1 0.14* 26 (8.3)
AFG2 −0.01 98.5 0.22*** 586 (98.5) 0.18 89.6 0.18* 2 (1.6) 0 8.0 0.12* 23 (7.3)
AFM1 0.38 94.8 0.25*** 553 (92.9) 0.26 87.2 0.27* 4 (3.2) 0 17.0 0.11 35 (11.2)
Alternaria Toxins Group total 0.15 96.6 0.20*** 573 (96.3) 0.13 72.8 0.12 7 (5.60) −0.02 20.0 0 58 (18.5)
Altenuene 0.05 93.1 0.23*** 552 (92.8) Not included Not included
AOH 0.11 95.6 0.25*** 567 (95.3) 0.10 90.4 0.10 1 (0.80) 0 7.3 0.08 14 (4.5)
AME 0.10 95.3 0.14*** 565 (95.0) 0.12 91.2 0.16 1 (0.80) 0 8.0 0.03 15 (4.8)
Altertoxin I 0.17 92.1 0.20*** 540 (90.8) Not included Not included
Tentoxin 0.06 91.3 0.27*** 540 (90.8) Not included Not included
TA 0.09 95.1 0.03 564 (94.8) 0.13 80.0 0.14 4 (3.2) 0 15.9 0 42 (13.4)
Beauvericin 0.33 71.9 0.28* 94 (15.8) Not included
Citrinin 0 99.0 n.a. 0 (0.0) −0.10 81.6 −0.10 0 (0.00) −0.02 90.1 −0.01 1 (0.30)
Diacetoxyscirpenol Group total n.a. 0.04 87.2 0.06 3 (2.40) n.a.
DAS −0.02 96.5 0.06 570 (95.8) −0.03 93.6 −0.03 0 (0.0) 0 9.8 0.09 24 (7.7)
MAS Not included −0.02 95.2 n.a. 0 (0.0) n.a.
NEO Not included 0.30 93.6 0.15 2 (1.60) n.a.
Enniatins Group total 0.25 65.0 0.69*** 119 (20.0) n.a. n.a.
Enniatin A 0.25 65.0 0.99*** 119 (20.0) Not included Not included
Enniatin A1 0.25 65.0 0.91*** 119 (20.0) Not included Not included
Enniatin B 0.25 65.0 0.51*** 119 (20.0) Not included Not included
EnB1 0.25 65.0 0.59*** 119 (20.0) 0.22 64.0 0.21* 22 (17.6) −0.14 50.0 −0.03 25 (8.0)
Ergot Alkaloids Group total 0.17 59.0 0.54** 141 (23.7) −0.03 52.0 0.08 16 (12.8) −0.01 52.5 −0.02 65 (20.8)
Eco 0.22 64.7 0.88*** 100 (16.8) −0.04 92.0 −0.04 0 (0.0) 0 61.7 −0.03 6 (1.9)
Econ 0.24 67.1 0.71*** 92 (15.5) −0.08 84.8 −0.08 0 (0.0) 0 59.2 −0.05 5 (1.6)
Ecr 0.17 59.0 0.28* 141 (23.7) −0.03 92.8 −0.04 0 (0.0) −0.02 49.2 −0.05 4 (1.3)
Ecrn 0.24 67.1 0.71*** 92 (15.5) −0.06 89.6 −0.06 0 (0.0) 0.02 64.4 −0.05 11 (3.5)
Ek 0.29 81.7 0.22 36 (6.1) −0.02 94.4 −0.03 0 (0.0) −0.05 78.4 −0.04 2 (0.6)
Ekn 0.29 81.7 0.22 36 (6.1) 0.07 88.8 0.06 1 (0.8) −0.05 78.6 −0.04 2 (0.6)
Em 0.23 67.9 0.72*** 80 (13.4) −0.02 95.2 −0.02 0 (0.0) 0 69.3 −0.02 4 (1.3)
Emn 0.24 70.3 0.74*** 72 (12.1) −0.03 92.8 −0.03 0 (0.0) 0.05 67.4 −0.03 3 (1.0)
Es 0.22 64.7 0.77*** 100 (16.8) 0.30 93.6 0.29** 2 (1.6) 0 62.1 −0.03 5 (1.6)
Esn 0.24 67.1 0.70*** 92 (15.5) 0.52 96.0 0.50*** 3 (2.4) 0.10 65.6 −0.05 14 (4.5)
Et 0.16 59.8 0.51*** 118 (19.8) −0.02 94.4 −0.03 0 (0.0) 0 56.1 −0.05 6 (1.9)
Etn 0.24 70.3 0.74*** 72 (12.1) −0.03 93.6 −0.03 0 (0.0) 0.09 68.8 −0.03 4 (1.3)
Fumonisins Group total 0.13 76.1 0.12 426 (71.6) 0 61.6 0.08 8 (6.4) −0.01 34.3 0.08 70 (22.4)
FB1 0.13 75.6 −0.01 422 (70.9) −0.05 72.8 −0.06 2 (1.6) 0.01 72.3 0.06 45 (14.4)
FB2 0.13 75.6 0.05 422 (70.9) 0.09 80.0 0.06 3 (2.4) −0.01 80.2 0.02 31 (9.9)
FB3 0.15 70.3 0.31 47 (7.9) 0 98.4 n.a. 0 (0.0) 0.02 69.2 −0.02 1 (0.3)
Ochratoxins Group total n.a. 0.37 70.4 0.44*** 26 (20.8) n.a.
OTA 0 100 0.09* 595 (100.0) 0.46 76.0 0.53*** 26 (20.8) 0 33.2 −0.02 103 (32.9)
OTα Not included −0.13 73.6 −0.14 0 (0.0) n.a.
PAT 0.19 98.7 0.01 586 (98.5) Not detected Not detected
ROQ-C Not included 0.44 94.4 0.50*** 3 (2.40) Not detected
STE 0.27 90.9 0.83*** 13 (2.20) 0.12 86.4 0.14 2 (1.60) −0.04 81.3 −0.03 2 (0.60)
T2 & HT2 Group total 0.18 72.3 0.10* 384 (64.5) 0.39 83.2 0.18* 10 (8.0) 0.01 27.4 0.08 61 (19.5)
HT2 0.09 85.5 0.10* 500 (84.0) −0.03 95.2 −0.02 0 (0.0) 0 12.1 0.12* 11 (3.5)
T2 0.13 85.9 0.08 500 (84.0) 0.39 87.2 0.37*** 7 (5.60) 0 23.8 0.09 46 (14.7)
T2OH3 Not included 0 98.4 n.a. 0 (0.0) n.a.
T2OH4 Not included −0.02 96.0 −0.02 0 (0.0) n.a.
Type B
Trichothecenes
Group total 0 99.7 0.36*** 593 (99.7) 0.12 59.2 0.12 19 (15.2) 0 37.7 0.06 116 (37.1)
3AcDON −0.04 92.4 0.22*** 550 (92.4) −0.03 92.0 −0.03 0 (0.0) 0 8.0 0.03 16 (5.1)
15AcDON −0.04 92.4 0.22*** 550 (92.4) 0.26 87.2 0.26 4 (3.20) 0.01 15.3 0.03 35 (11.2)
DOM Not included 0.03 86.4 0.03 1 (0.80) n.a.
DON 0 99.2 0.17*** 590 (99.2) 0.25 78.4 0.25 8 (6.4) 0 17.3 0.16* 54 (17.3)
DON3Glu 0.28 84.0 0.53** 28 (4.7) −0.04 92.0 −0.04 0 (0.0) −0.02 83.0 −0.05 2 (0.6)
F-X 0.38 82.4 0.54* 50 (8.4) Not detected n.a.
NIV 0.17 94.8 0.20*** 560 (94.1) −0.01 96.8 −0.01 0 (0.0) 0 3.2 0.01 6 (1.9)
(continued on next page)
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short-term fluctuations in actual mycotoxin consumption, or even un-
characterized cultural differences in food preparation. The manifold
variables affecting differential contamination of consumed foods, as
compared to the single median EFSA value taken to represent all five
European countries, remain to be fully elucidated, as well as factors
affecting mycotoxin uptake, metabolism, and excretion (i.e., mycotox-
icokinetics).
4.2. Comparison of external and internal mycotoxin exposure estimates
In the present study, dissimilar results were obtained between 24-
HDR and biological sampling (Gerding et al., 2014; Ritieni et al., 2010).
The primary explanation for this is the difference between the cross-
sectional measurements, both spatially and temporally. EFSA con-
tamination data (24-HDR) in raw agricultural commodities are regional
and seasonal, while biological samples illustrate heterogeneity of dis-
tribution across individuals and over the time course of ingestion,
metabolism, and excretion. This supports the contrast in a number of
co-exposed mycotoxins detected between dietary mycotoxin exposure
by 24-HDR and biological fluids (Fig. 2). On average, the study popu-
lation was found to have one third as many different mycotoxins co-
detected in biological samples, as compared to the number of myco-
toxins calculated by 24-HDR.
The estimation of dietary exposure by means of 24-HDR relied on
mycotoxin occurrence data from EFSA, which are regionally re-
presentative and contemporary to the sampling period. This instrument
was validated in assessments of both nutrients and pesticide con-
taminants (Crispim et al., 2011; van Klaveren et al., 2012). Nutrients
are regularly produced within food crops, and pesticides are relatively
uniformly applied to crops, but also rapidly degrade (Darko and Akoto,
2008). By contrast, mycotoxin contamination is heterogeneously dis-
tributed, yet are reportedly very stable, and degradation often requires
extremes of temperature and pressure (De Ruyck et al., 2015; Milani,
2013; Milani and Maleki, 2014; Schaafsma and Hooker, 2007). The
mechanisms of production and distribution of these 3 classes of food-
borne molecules differ substantially. As a consequence, tools for as-
sessing food-distribution should be considerably tailored in order to
describe any one of them accurately.
Additionally, some mycotoxins are metabolized into different forms
as they pass from the blood to the urine, further adding the complexity
that must be targeted in order to survey a population effectively
(Nathanail et al., 2015). For 12 individual mycotoxins (AFB2, AFG1,
AFG2, AFM1, DAS, NEO, Ecrn, Esn, FB1, FB2, T2 & ZEN) detection rates
between blood and urine agreed well according to both Cohen’s K and
percentage agreement (Table 6, serum vs. mean 24hr urine). Further,
almost all mycotoxins were significantly positively associated as shown
by the Spearman's rho. This serves as a confirmation that the variable
distribution of mycotoxin contaminants in the food supply can be de-
scribed by surveys at the level of the individual. Observing significant
correlations across almost all mycotoxins, when comparing serum to
the 2 urinary measurements, with all three samples taken weeks apart,
also strongly supports chronic exposure of the study population. Fur-
ther, observing significant correlations in individuals between detect-
able levels of mycotoxins in their blood and urine implies that it is
possible to identify and validate exposure in a consistent way between
two different types of measurements.
Nevertheless, the quantitative levels of mycotoxin contamination
described by biological sampling did not correlate well with the 24-
HDR data. Mycotoxin exposure is represented homogenously over 24 h.
However, mycotoxins are only transiently present in each biological
fluid, and residency periods vary wildly (Yang et al., 2015; Reddy and
Bhoola, 2010). This temporal heterogeneity may serve to partly explain
the discrepancy in detection rates between 24-HDR and biological
samples. In order to detect a mycotoxin in a biological fluid sample,
that fluid must be sampled at a specific time when the mycotoxin has
been consumed. In order to correlate with a 24-HDR, it would be ne-
cessary to ensure biological sampling takes place at the correct time
after consumption of the dietary contaminant.
Unfortunately, the optimal time to take a single blood sample would
not be uniform across various mycotoxins with varying rates of meta-
bolism. Fortunately, continuous collection of urine samples is some-
what more accessible than multiple venipunctures per day and can be
used to address this issue. In the present study, urine was collected over
the same 24 h covered by the 24-HDR. However, urine collected early
in the day would be the product of the previous night’s dinner. Some
mitigation against this confounding factor can be found in the study
design selecting an age group that is expected to lead relatively regular
lifestyles. For example, several type B trichothecenes are eliminated
from the blood and urine within 6 h after ingestion (Vidal et al., 2018).
Therefore, DON-contaminating foods eaten with dinner on the night,
prior to recording a 24-HDR, may be excreted in the collected urine
sample; the opposite situation is also possible with cereal-based pro-
ducts reported consumed late in the 24-HDR not being excreted until
after the urine collection period. Another observation is the correlation
of 4 mycotoxins (AFG1, AFG2, DON and HT2) between 24-HDR and
urine when comparing single days’ measurements (Table 5), while
comparing the two-day means of each method did not yield significant
positive correlations (Table 6). Hence, the true effect of this
Table 5 (continued)
Mycotoxins 2x 24-HDR, n = 595 2x 24hr Urine, n = 125 24-HDR vs 24hr Urine, n = 313
K % agr ρ +ve (%) K % agr ρ +ve (%) K % agr ρ +ve (%)
VER Not included 0 98.4 0 0 (0.0) n.a.
Zearalenone Group total 0 99.5 0.32 592 (99.5) 0.02 69.6 0.02 5 (4.0) 0 19.8 0 60 (19.2)
αZEL 0.19 94.1 0.81 5 (0.8) 0.18 89.6 0.18 2 (1.6) 0 89.1 −0.02 1 (0.3)
βZEL 0.19 94.1 0.18 5 (0.8) −0.04 80.0 −0.04 1 (0.8) −0.04 84.3 −0.02 1 (0.3)
ZAN −0.01 98.3 n.a. 0 (0.0) −0.01 97.6 −0.01 0 (0.0) −0.01 98.4 −0.01 0 (0.0)
ZEN 0 99.2 −0.02 590 (99.2) 0 96.8 0 0 (0.0) 0 2.2 0.05 6 (1.9)
Legend: The percentage of recurring positive or recurring negative detections (% agreement) and Cohen’s kappa (Κ) describe agreement between time points in terms
of positive/negative screening. Counting non-detections as zero, Spearman’s rho (ρ) was calculated. Significant correlations are denoted * for p ≤ 0.05; ** for
p ≤ 0.01; *** for p ≤ 0.001. The number of individuals (%) of intersecting positive detections was also counted (+ve). Mycotoxin abbreviations are as follows: 3-
acetyl deoxynivalenol (3AcDON); 15-acetyl deoxynivalenol (15AcDON); aflatoxin B1 (AFB1); aflatoxin B2 (AFB2); aflatoxin G1 (AFG1); aflatoxin G2 (AFG2);
aflatoxin M1 (AFM1); alpha zearalenol (αZEL); alternariol (AOH); alternariol methyl ether (AME); beta zearalenol (βZEL); citrinin (CIT); creatinine (CTN); dee-
poxydeoxynivalenol (DOM); deoxynivalenol (DON); deoxynivalenol-3-glucoside (DON3Glu); diacetoxyscirpenol (DAS); dihydroergotamine (DHEt); enniatin B1
(EnB1); ergocornine (Eco); ergocristine (Ecr); ergokryptine (Ek); ergometrine (Em); ergosine (Es); ergotamine (Et); and their respective epimers (Econ; Ecrn; Ekn;
Emn; Esn; and Etn; respectively); fumonisin B1 (FB1); fumonisin B2 (FB2); fumonisin B3 (FB3); fusarenone X (F-X); HT-2 toxin (HT2); methylergometrine (MeEm);
neosolaniol (NEO); nivalenol (NIV); ochratoxin A (OTA); ochratoxin α (OTα); patulin (PAT); roquefortine C (ROQ-C); sterigmatocystin (STE); T-2 toxin (T2); T-2
toxin tetraol (T2OH4); T-2 toxin triol (T2OH3); verrucarol (VER); zearalanone (ZAN); zearalenone (ZEN).
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confounding mechanism remains to be clearly elucidated.
Also, in comparing biological samples with 24-HDR exposures, an-
other key variable is the rate of uptake. Mycotoxins vary wildly in rates
of intestinal absorption, and these rates may be further affected by co-
exposures with other mycotoxins, or even varying dietary composition
(Gonzalez et al., 2013; Grenier and Oswald, 2011). Reviews report the
complexity to assess the effects of dietary composition on mycotoxin
absorption (Gonzalez et al., 2013; Grenier and Oswald, 2011). Hence,
models to accurately predict the intestinally absorbed fraction of oral
mycotoxin intake remain to be constructed. The development of such
models has implications for assessments of risk associated with myco-
toxin contamination (Mengelers et al., 2018).
Table 6
Statistical comparisons over intersecting populations between measurement types. The mean 24-HDR for each individual was compared to their mean 24-hour urine
and to the serum measurement, where available.
Mycotoxins Mean 24-HDR vs Serum, n = 268 Mean 24-HDR vs mean 24hr Urine, n = 188 Serum vs mean 24hr Urine, n = 147
K % agr ρ +ve (%) K % agr ρ +ve (%) K % agr ρ +ve (%)
Aflatoxins Group total 0.01 58 −0.11 154 (57) 0 51 −0.01 97 (52) 0.52 76 0.49*** 60 (41)
AFB1 0 15 0.01 39 (15) 0 11 −0.01 20 (11) 0.31 84 0.23*** 8 (5)
AFB2 0 27 −0.03 73 (27) 0 23 −0.01 44 (23) 0.44 80 0.43*** 19 (13)
AFG1 0 3 0.02 7 (3) 0 1 −0.07 2 (1) 0.49 99 0.49*** 1 (1)
AFG2 0 16 0.03 44 (16) 0 11 0.20 21 (11) 0.54 90 0.51*** 11 (7)
AFM1 0 22 0 54 (20) 0 20 0 32 (17) 0.56 84 0.57*** 22 (15)
Alternaria Toxins Group total Not detected in serum −0.01 28 0.06 54 (29) Not detected in serum
AME 0 8 −0.08 14 (7)
AOH 0 8 0.03 14 (7)
TA −0.01 20 0.09 38 (20)
CIT 0.05 85 0.09 2 (1) −0.04 84 −0.06 2 (1) 0.03 78 0 3 (2)
Diacetoxyscirpenol Group total 0 31 0.01 84 (31) 0 19 0.05 38 (20) 0.40 76 0.52*** 21 (14)
DAS 0 23 0 61 (23) 0 13 0.05 25 (13) 0.43 80 0.51*** 17 (12)
NEO Not included in 24-HDR dataset Not included in 24-HDR dataset 0.41 93 0.40*** 4 (3)
Enniatin B1 Not detected in serum −0.17 41 −0.20** 36 (19) Not detected in serum
Ergot Alkaloids Group total 0.03 51 0.09 97 (36) −0.08 53 −0.08 79 (42) 0.18 58 0.28*** 58 (39)
Eco 0.01 60 0 6 (2) −0.06 55 −0.07 4 (2) −0.03 90 −0.04 0 (0)
Econ −0.05 58 −0.04 11 (4) −0.02 56 0 8 (4) 0.29 84 0.28*** 7 (5)
Ecr 0 48 0.01 10 (4) −0.02 44 −0.05 7 (4) 0.29 92 0.30*** 3 (2)
Ecrn −0.03 60 −0.03 7 (3) 0.02 59 0.02 8 (4) 0.44 93 0.43*** 5 (3)
Ek 0 1 −0.10 4 (1) 0 5 −0.05 9 (5) 0.27 97 0.27*** 2 (1)
Ekn 0.03 74 0.02 6 (2) −0.11 66 −0.15 1 (1) −0.01 93 −0.02 0 (0)
Em 0.03 73 0.06 4 (1) 0.01 72 0.03 2 (1) −0.02 96 −0.02 1 (1)
Emn 0.02 74 0.03 5 (2) 0.01 71 0.04 3 (2) 0.13 93 0.12 0 (0)
Es −0.03 57 −0.05 11 (4) 0 58 0 4 (2) 0.21 88 0.25* 3 (2)
Esn 0 61 0.03 11 (4) 0.08 61 0.13 10 (5) 0.49 92 0.49*** 7 (5)
Et 0.07 60 0.15* 10 (4) −0.03 52 −0.02 3 (2) 0.28 91 0.27*** 3 (2)
Etn −0.01 77 −0.03 0 (0) 0.09 73 0.13 5 (3) 0 97 n.a. 0 (0)
Fumonisins Group total 0.01 43 0.03 113 (42) 0 55 0.04 76 (40) 0.40 71 0.39*** 40 (27)
FB1 0 32 0.04 75 (28) 0 29 0.03 46 (24) 0.47 79 0.46*** 25 (17)
FB2 0 19 −0.07 40 (15) −0.01 22 0 32 (17) 0.22 78 0.24** 9 (6)
FB3 0.05 79 0.07 4 (1) 0.05 80 0.07 0 (0) 0.38 96 0.39*** 1 (1)
Ochratoxins Group total 0.01 43 0.09 115 (43) 0 48 0.14 92 (49) 0.06 55 −0.05 24 (16)
OTA 0 39 0.13* 104 (39) 0 40 0.13 76 (40) 0.05 56 −0.07 22 (15)
OTα Not included in 24-HDR dataset Not included in 24-HDR dataset 0.14 86 0.31*** 2 (1)
ROQ-C Not included in 24-HDR dataset Not included in 24-HDR dataset 0.14 86 0.31*** 2 (1)
STE 0.12 81 0.13* 7 (3) −0.04 4 3 −0.06 4 (2) 0.18 84 0.18* 4 (3)
T2 & HT2 Group total 0.01 38 0.07 100 (37) 0.02 31 0 58 (31) 0.57 82 0.53*** 32 (22)
HT2 0 15 0 37 (14) 0 9 −0.04 12 (6) 0.31 93 0.32*** 3 (2)
T2 0.01 27 0.05 68 (25) 0.01 24 0 41 (22) 0.53 82 0.55*** 25 (17)
Type B
Trichothecenes
Group total −0.01 42 −0.01 114 (43) 0 52 0.04 99 (53) 0.37 69 0.28*** 38 (26)
AcDON 0 8 0.15* 22 (8) 0 23 −0.06 44 (23) 0.32 86 0.30*** 7 (5)
DOM Not included in 24-HDR dataset Not included in 24-HDR dataset 0.25 90 0.32** 3 (2)
DON 0 14 −0.06 38 (14) 0 24 −0.05 46 (24) 0.39 80 0.37*** 15 (10)
DON3Glu 0.07 75 0.07 8 (3) −0.05 78 −0.06 1 (1) −0.05 90 −0.05 2 (1)
F-X 0.05 75 0.06 5 (2) Not detected in urine Not detected in urine
NIV −0.01 8 0.02 21 (8) 0 3 0.09 6 (3) 0.21 92 0.23* 2 (1)
Zearalenone Group total 0.01 30 −0.03 83 (31) 0 28 0.03 54 (29) 0.30 70 0.29*** 24 (16)
αZEL −0.04 82 −0.06 2 (1) −0.08 85 −0.08 0 (0) 0.03 78 0.36*** 8 (5)
βZEL 0.12 82 0.14 6 (2) −0.05 77 −0.06 0 (0) 0.43 80 0.23* 11 (7)
ZAN Not detected in serum −0.02 96 −0.02 0 (0) Not detected in serum
ZEN −0.05 2 −0.05 5 (2) 0 4 −0.02 6 (3) 0.49 99 0.58*** 2 (1)
Legend: Cohen’s kappa (Κ) +/- describes agreement between methods in terms of mycotoxin detection rate, and Spearman’s rho (ρ) total describes associations after
values below quantification were replaced with zero; significant correlations are denoted * for p ≤ 0.05; ** for p ≤ 0.01; *** for p ≤ 0.001. The number of
individuals (%) of individuals who tested positive to both of each pair of measurement types is also listed (2x + ve). Mycotoxin abbreviations are as follows: 3-acetyl
deoxynivalenol (3AcDON); 15-acetyl deoxynivalenol (15AcDON); aflatoxin B1 (AFB1); aflatoxin B2 (AFB2); aflatoxin G1 (AFG1); aflatoxin G2 (AFG2); aflatoxin M1
(AFM1); alpha zearalenol (αZEL); alternariol (AOH); alternariol methyl ether (AME); beta zearalenol (βZEL); citrinin (CIT); creatinine (CTN); deepoxydeoxynivalenol
(DOM); deoxynivalenol (DON); deoxynivalenol-3-glucoside (DON3Glu); diacetoxyscirpenol (DAS); dihydroergotamine (DHEt); enniatin B1 (EnB1); ergocornine
(Eco); ergocristine (Ecr); ergokryptine (Ek); ergometrine (Em); ergosine (Es); ergotamine (Et); and their respective epimers (Econ; Ecrn; Ekn; Emn; Esn; and Etn;
respectively); fumonisin B1 (FB1); fumonisin B2 (FB2); fumonisin B3 (FB3); fusarenone X (F-X); HT-2 toxin (HT2); methylergometrine (MeEm); neosolaniol (NEO);
nivalenol (NIV); ochratoxin A (OTA); ochratoxin α (OTα); patulin (PAT); roquefortine C (ROQ-C); sterigmatocystin (STE); T-2 toxin (T2); T-2 toxin tetraol (T2OH4);
T-2 toxin triol (T2OH3); verrucarol (VER); zearalanone (ZAN); zearalenone (ZEN
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Over time, it is also possible for some mycotoxins to accumulate in
the blood, which is gradually renewed over the course of several weeks,
in contrast to urine, which is generally excreted within hours of pro-
duction. The associations observed between the presence of some my-
cotoxins in the blood and urine samples taken several weeks later
supports assumptions regarding the regularity of diet, as well as con-
tamination.
Finally, besides contaminants, the 24-HDR instrument is also eval-
uated in literature with regard to e.g., sodium consumption (McLean
et al., 2018). Interestingly, on consideration of 14 studies validating 24-
HDR, this systematic review recommended urinary analyses remain the
gold standard to assess individuals’ intake of dietary substances. It was
also suggested that up to seven samples taken on non-consecutive days
should be considered, in order to obtain an assessment within reliability
for clinical assessments. Unfortunately, only two 24-h urine collections
were available in EFCOVAL, limiting our analyses to single time-point
exposures rather than long-term exposures. In the present work, this
recommendation was supported in the case of 24-h urine collections
and also by 24-HDR assessments by the very low Cohen’s K values
calculated between detection rates at the two time points, despite high
percentages of agreement. Hence, more time points should be in-
vestigated in order to find further evidence of either under-estimation
from direct sampling or over-estimation from indirect sampling
methods. A different meta-analysis of five studies also compared the 24-
HDR to biomarker measurements, calculating attenuation factors for
each measurement type to a separately calculated true usual intake for
four factors i.e., energy, protein, potassium, and sodium (Freedman
et al., 2017). A picture emerges of considerable discrepancy between
what is measured by either the 24-HDR or biological fluid sampling.
This is in support of Freedman's recommendations that the 24-HDR is
not ideal for assessing long-term exposures, where biomarkers were
reportedly better correlated to true usual intake (Freedman et al.,
2017).
4.3. Limitations and bias of the present study
The principal inaccuracy of a 24-HDR in this research is the as-
sumption that mycotoxins are homogeneously distributed throughout
each type of food, in all of Europe and in that year (Paoletti and
Esbensen, 2015). Though the median recorded EFSA contamination
level was uniformly applied to all intakes of a food item, it has never
been reported that the incidence of any mycotoxin reaches 100% in
European food products. Even in the hypothetical case of total in-
cidence and universally homogenous distribution, variations in food
preparation (washing, sectioning, mixing, etc.) could affect rates of
availability and uptake. Further, interpersonal differences in judgment
on whether a given food item is considered “too moldy to eat” may
affect actual mycotoxin intake (e.g. moldy fruit) (Ouhibi et al., 2019).
The principal weakness of quantitative analysis on biological sam-
ples is the left-censoring of the dataset due to the minimum detectable
concentrations of target analytes (Wei et al., 2018). An additional
vulnerability in assaying biological samples is the possibility for target
components to exist in metabolized or otherwise modified forms, thus
escaping targeted analysis (Righetti et al., 2016). This is further con-
founded by the assumption that metabolic rates and pathways are
uniform between individuals in the study population; the effects of
genetic variation on the production of various metabolites remain
poorly understood.
Both the calculated dietary intake data as well as the measured
urinary data are prone to bias due to the day of assessment if only one
single measurement was available, and the individual ceased partici-
pation in the study prior to the second sampling. Long-term exposures
require evaluation either by repeated cross-sectional assessments or
with tools specifically designed for longitudinal assessment of dietary
exposures, which may be partially achieved with food frequency
questionnaires (not available in EFCOVAL).
After the 24-HDR, classification of consumed food items was done
according to the FoodEx1 system, since deprecated in favor of FoodEx2
(revision 2) (EFSA, 2016).
Also, the biological samples obtained from the EFCOVAL Project
were stored at −80 °C for over a decade. In the course of the present
analysis, one cycle of thawing and freezing was required in order to
aliquot large sample volumes. The stability of mycotoxins under these
conditions has not been comprehensively addressed in the literature.
According to the acquired results and by broadcasting the limita-
tions and bias of the present study, it is clear that in future research
there is a strong need for more standardized and harmonized occur-
rence data in foods, covering multiple mycotoxin profiles.
5. Conclusion
According to the study results, the continuous monitoring of myco-
toxin contamination in raw agricultural commodities remains to be
prioritized. However, the use of biological sampling for surveys of dietary
exposure to mycotoxins describes real dietary mycotoxin occurrence in
higher resolution than calculations based on a database. Further, myco-
toxin exposure measurements made in biological fluids seem to inform
studies of single exposure better than chronic exposure. As such, myco-
toxin exposure assessments of either the external method of dietary sur-
veys or internal method of biological fluid sampling, illustrate different
aspects of real-world mycotoxin exposure. Taken together, these mea-
surements appear insufficient for holistically describing real exposure, due
to many uncontrolled factors that lead to uncharacterized variance in the
dataset. There is a growing interest in longitudinal monitoring of an ac-
curately determined dietary contaminant intake, through periodic blood
and urine collection over the course of absorption, metabolism, and ex-
cretion. Particularly, metabolomic profiling of dietary mycotoxin ex-
posures could help not only with a comprehensive assessment of single
exposures, but also with the identification of specifically chronic exposure
biomarkers. Such detailed characterization would help inform population
exposure assessments and aid in the interpretation of cross-sectional sur-
veys. Considering the implicitly chronic nature of dietary exposure, as well
as the variety of a modern diet, modelling real-world exposure requires a
simultaneous assessment of multiple mycotoxins (Warth et al., 2013).
Determining and monitoring mycotoxin presence informs assessments of
food safety either by indirectly evaluating a population's probable external
exposure or by directly quantifying internal exposure through biomarker
analysis (Abrunhosa et al., 2016; Gerding et al., 2014; Heyndrickx et al.,
2015; Wallin et al., 2015).
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